BOVIE MEDICAL CORPORATION TO RELEASE THIRD QUARTER 2017 FINANCIAL RESULTS ON NOVEMBER 2, 2017

CLEARWATER, FL — October 17, 2017 – Bovie Medical Corporation (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the third quarter of 2017 will be released after the market closes on Thursday, November 2.

Management will host a conference call at 4:30 p.m. Eastern Time on November 2 to discuss the results of the quarter and host a question and answer session. To listen to the call by phone, interested parties may dial 844-507-6493 (or 647-253-8641 for international callers) and provide access code 95898318. Participants should ask for the Bovie Medical Corporation Call. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website and at:
https://event.on24.com/wcc/r/1472820/04D7A7087BD18CA1B64C4A121242427B.

A telephonic replay will be available approximately two hours after the end of the call through November 16, 2017. The replay can be accessed by dialing 800-585-8367 for U.S. callers or 416-621-4642 for International callers and using the replay access code: 95898318. The webcast will be archived on the Investor Relations section of the Company’s website.

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of plasma that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. The new J-Plasma® handpieces with Cool-Coag™ technology deliver the precision of helium plasma energy, the power of traditional monopolar coagulation and the efficiency of plasma beam coagulation – enabling thin-layer ablation and dissection and fast coagulation with a single instrument, minimizing instrument exchange and allowing a surgeon to focus on their patient and their procedures. With Cool-Coag technology, the new J-Plasma handpieces can deliver three distinctly different energy modalities – further increasing the utility and versatility of the J-Plasma system. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, IDS™ and DERM™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation at www.boviemedical.com.

Investor Relations Contact:

Westwicke Partners on behalf of Bovie Medical Corporation
Mike Piccinino, CFA
Managing Director
443-213-0500
investor.relations@boviemed.com

Top